McKesson Corp (MCK): The Quiet Rise of Oncology and Biopharma Services— What’s the Impact, Valuation Outlook & its 5 Key Catalysts ?

McKesson’s fiscal Q3 2026 results reinforce the durability of its pharmaceutical distribution and biopharma services model, with revenue rising 11% year-over-year to $106.2B and adjusted EPS increasing 16% to $9.34, prompting management to raise full-year EPS guidance to $38.80–$39.20, implying 17–19% growth. The Oncology & Multispecialty platform continues to emerge as the core growth engine, with revenue up 37% and operating profit increasing 57%, driven by provider expansion, specialty product growth, and acquisitions including PRISM Vision and Florida Cancer Specialists. Even excluding M&A, operating profit grew 15%, reflecting strong organic demand and improving margin dynamics supported by biosimilar adoption and digital physician enablement. Prescription Technology Solutions also delivered strong operating leverage, with operating profit rising 18% as automation and affordability programs expanded across biopharma partners. Meanwhile, North American Pharmaceutical distribution remained resilient, supported by specialty demand and GLP-1 therapy growth, which generated $14B in quarterly distribution revenue and accounted for a significant share of segment expansion. Portfolio optimization remains underway with the planned Medical-Surgical separation targeting 2027, potentially sharpening investor focus on higher-growth specialty and services businesses. With strong cash generation and continued capital returns, McKesson appears well positioned operationally, but its long-term growth narrative increasingly hinges on specialty and services scaling. As oncology services, GLP-1 distribution, and patient access platforms expand, can McKesson sustain double-digit earnings growth while navigating evolving drug pricing and reimbursement policy dynamics?